Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 19/20 | 1.00 |
| ▸ | CX3CR1 | P49238 | 17/20 | 1.00 |
| ▸ | HTR1B | P28222 | 1/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23828038 | 0.91 | CX3CR1 (0.84) | CXCR2CX3CR1ADORA1 | |
| SCHEMBL214888 | 0.91 | CX3CR1 (0.84) | CXCR2CX3CR1ADORA1 | |
| SCHEMBL31199207 | 0.91 | CX3CR1 (0.84) | CXCR2CX3CR1ADORA1 | |
| SCHEMBL23828035 | 0.91 | CX3CR1 (0.84) | CXCR2CX3CR1ADORA1 | |
| SCHEMBL212454 | 0.87 | CXCR2 (0.81) | CXCR2CX3CR1HTR1BADORA1 | |
| SCHEMBL212918 | 0.85 | CXCR2 (0.75) | CXCR2CX3CR1HTR1BADORA1 | |
| SCHEMBL215277 | 0.83 | CX3CR1 (1.00) | CXCR2CX3CR1ADORA1 | |
| SCHEMBL212362 | 0.83 | CXCR2 (0.82) | CXCR2CX3CR1ADORA1 | |
| SCHEMBL23828048 | 0.82 | CXCR2 (0.70) | CXCR2CX3CR1ADORA1 | |
| SCHEMBL21615509 | 0.82 | CXCR2 (0.70) | CXCR2CX3CR1ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088780-B2 | 5,7-disubstituted thiazolo[4,5-D]pyrimidines for the selective inhibition of chemokine receptors | ASTRAZENECA AB (SE) | 2012-01-03 | — | — | US | claimed |
| US-20090124637-A1 | Novel 5,7-Disubstituted [1,3]Thiazolo[4,5-D]Pyrimidin-2(3H)-One Derivatives 794 | ASTRAZENECA AB (SE) | 2009-05-14 | — | — | US | claimed |
| US-8088780-B2 | 5,7-disubstituted thiazolo[4,5-D]pyrimidines for the selective inhibition of chemokine receptors | ASTRAZENECA AB (SE) | 2012-01-03 | — | — | US | disclosed |
| US-20090124637-A1 | Novel 5,7-Disubstituted [1,3]Thiazolo[4,5-D]Pyrimidin-2(3H)-One Derivatives 794 | ASTRAZENECA AB (SE) | 2009-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124637-A1 | Novel 5,7-Disubstituted [1,3]Thiazolo[4,5-D]Pyrimidin-2(3H)-One Derivatives 794 | CX3CR1, CCR2, CCR5 | CXCR2 5/4885CX3CR1 1/4885HTR1B 907/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.